Designing Safer Analgesics via μ-Opioid Receptor Pathways

Trends in Pharmacological Sciences

Volumn 38, Issue 11, 2017, Pages 1016-1037

  Chan, H C Stephen ^a,b   McCarthy, Dillon ^c   Li, Jianing ^c   Palczewski, Krzysztof ^d   Yuan, Shuguang ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITY OF VERMONT   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

computational biology; drug discovery; GPCR; opioid receptor; safer painkiller

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BU 08028; BUPRENORPHINE; CODEINE; DICLOFENAC; DIFLUNISAL; FENTANYL; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NAPROXEN; OLICERIDINE; OXYCODONE; PARACETAMOL; PETHIDINE; PZM 21; REMIFENTANIL; SALICYLIC ACID; SB 612111; ST 034307; SULINDAC; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; CONSTIPATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM;

ANALGESICS, OPIOID; ANIMALS; DRUG DESIGN; HUMANS; RECEPTORS, OPIOID, MU;

EID: 85029526133     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.08.004     Document Type: Review

References (79)

1. Kosten, T.R., George, T.P., The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 1 (2002), 13–20.
2. Contet, C., et al. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14 (2004), 370–378.
3. Stein, C., Opioid receptors. Annu. Rev. Med. 67 (2016), 433–451.
4. Huang, W., et al. Structural insights into mu-opioid receptor activation. Nature 524 (2015), 315–321.
5. Pasternak, G.W., Pan, Y.X., Mu opioids and their receptors: evolution of a concept. Pharmacol. Rev. 65 (2013), 1257–1317.
6. Siuda, E.R., et al. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr. Opin. Pharmacol. 32 (2016), 77–84.
7. Rasmussen, S.G., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477 (2011), 549–555.
8. Watson, H., Biological membranes. Essays Biochem. 59 (2015), 43–69.
9. Manglik, A., et al. Structural insights into the dynamic process of beta2-adrenergic receptor signaling. Cell 161 (2015), 1101–1111.
10. Manglik, A., et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537 (2016), 185–190.
11. Luttrell, L.M., Lefkowitz, R.J., The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115 (2002), 455–465.
12. Tobin, A.B., G-protein-coupled receptor phosphorylation: where, when and by whom. Br. J. Pharmacol. 153:Suppl. 1 (2008), S167–S176.
13. Shukla, A.K., et al. Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497 (2013), 137–141.
14. Cahill, C.M., et al. Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol. Sci. 37 (2016), 963–976.
15. Manglik, A., et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485 (2012), 321–326.
16. Trzaskowski, B., et al. Action of molecular switches in GPCRs – theoretical and experimental studies. Curr. Med. Chem. 19 (2012), 1090–1109.
17. Yuan, S., et al. The molecular mechanism of P2Y1 receptor activation. Angew. Chem. Int. Ed. Engl. 55 (2016), 10331–10335.
18. Yuan, S., et al. Mechanistic studies on the stereoselectivity of the serotonin 5-HT1A receptor. Angew. Chem. Int. Ed. Engl. 55 (2016), 8661–8665.
19. Stoddart, L.A., et al. Effect of a toggle switch mutation in TM6 of the human adenosine A(3) receptor on Gi protein-dependent signalling and Gi-independent receptor internalization. Br. J. Pharmacol. 171 (2014), 3827–3844.
20. McAllister, S.D., et al. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 279 (2004), 48024–48037.
21. Yuan, S., et al. W246 opens a gate for a continuous intrinsic water pathway during activation of the adenosine A receptor. Angew. Chem. Int. Ed. Engl. 54 (2014), 556–559.
22. Rasmussen, S.G.F., et al. Crystal structure of the beta2 adrenergic receptor–Gs protein complex. Nature, 477, 2011, 549.
23. Kruse, A.C., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504 (2013), 101–106.
24. Vanni, S., et al. Observation of ‘ionic lock’ formation in molecular dynamics simulations of wild-type beta 1 and beta 2 adrenergic receptors. Biochemistry 48 (2009), 4789–4797.
25. Isberg, V., et al. Generic GPCR residue numbers – aligning topology maps while minding the gaps. Trends Pharmacol. Sci. 36 (2015), 22–31.
26. Katritch, V., et al. Structure–function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 531–556.
27. Link, A., Muller, C.E., G-protein-coupled receptors: sustained signaling via intracellular megaplexes and pathway-specific drugs. Angew. Chem. Int. Ed. Engl. 55 (2016), 15962–15964.
28. Manglik, A., et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537 (2016), 185–190.
29. Fenalti, G., et al. Structural basis for bifunctional peptide recognition at human delta-opioid receptor. Nat. Struct. Mol. Biol. 22 (2015), 265–268.
30. Wu, H., et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485 (2012), 327–332.
31. Nickolls, S.A., et al. Co-expression of GRK2 reveals a novel conformational state of the micro-opioid receptor. PLoS One, 8, 2013, e83691.
32. Khroyan, T.V., et al. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward. J. Pharmacol. Exp. Ther. 336 (2011), 952–961.
33. Reinscheid, R.K., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995), 792–794.
34. Toll, L., et al. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol. Rev. 68 (2016), 419–457.
35. Murphy, N.P., et al. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. 832 (1999), 168–170.
36. Ding, H., et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E5511–E5518.
37. Lambert, D.G., The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat. Rev. Drug Discov. 7 (2008), 694–710.
38. Li, J.X., Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 10225–10227.
39. Filizola, M., et al. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J. Comput. Aided Mol. Des. 15 (2001), 297–307.
40. Spahn, V., et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science 355 (2017), 966–969.
41. Mansour, A., et al. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 68 (1997), 344–353.
42. Brust, T.F., et al. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Sci. Signal., 10, 2017, aah5381.
43. Jamshidi, R.J., et al. Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons. J. Pharmacol. Exp. Ther. 355 (2015), 174–182.
44. Kang, J.S., et al. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 14 (2009), 363–380.
45. Weber, H.C., Opioid-induced constipation in chronic noncancer pain. Curr. Opin. Endocrinol. Diabetes Obes. 23 (2016), 11–17.
46. Nygaard, R., et al. The dynamic process of beta2-adrenergic receptor activation. Cell 152 (2013), 532–542.
47. Warolin, C., Pierre-Jean Robiquet. Rev. Hist. Pharm., 47, 1999 97–110 (in French).
48. Howard-Jones, N., A critical study of the origins and early development of hypodermic medication. J. Hist. Med. Allied Sci. 2 (1947), 201–249.
49. Erickson, D., Painkiller. There's still room for luck in industrial chemistry. Sci Am, 265, 1991, 101.
50. De La Cruz, J.P., et al. Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers. Fundam. Clin. Pharmacol. 17 (2003), 363–372.
51. Van Zee, A., The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am. J. Public Health 99 (2009), 221–227.
52. Waldhoer, M., et al. Opioid receptors. Annu. Rev. Biochem. 73 (2004), 953–990.
53. Castro, J.D., et al. Regional Opioid Analgesia: Physiopharmacological Basis, Drugs, Equipment, and Clinical Application. 1991, Kluwer Academic Publishers.
54. Benedetti, C., et al. Opioid Analgesia: Recent Advances in Systemic Administration. 1990, Raven Press.
55. Oldendorf, W.H., et al. Blood–brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178 (1972), 984–986.
56. De Leo, J.A., et al. Immune and Glial Regulation of Pain. 2007, IASP Press.
57. Zagon, I.S., et al. The biology of the opioid growth factor receptor (OGFr). Brain Res. Brain Res. Rev. 38 (2002), 351–376.
58. Pasternak, G., Pan, Y.X., Mu opioid receptors in pain management. Acta Anaesthesiol. Taiwan. 49 (2011), 21–25.
59. Rose, A.S., et al. Role of structural synamics at the receptor G protein interface for signal transduction. PLoS One, 10, 2015, e0143399.
60. Geppetti, P., et al. G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron 88 (2015), 635–649.
61. Heng, B.C., et al. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol. Adv. 31 (2013), 1676–1694.
62. Katritch, V., et al. Allosteric sodium in class A GPCR signaling. Trends Biochem. Sci. 39 (2014), 233–244.
63. Kobilka, B.K., G protein coupled receptor structure and activation. Biochim. Biophys. Acta 1768 (2007), 794–807.
64. Rees, S., et al. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 8 (2002), 261–268.
65. Soergel, D.G., et al. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155 (2014), 1829–1835.
66. Ordóñez Gallego, A., et al. Oxycodone: a pharmacological and clinical review. Clin. Transl. Oncol. 9 (2007), 298–307.
67. Ghanem, C.I., et al. Acetaminophen from liver to brain: new insights into drug pharmacological action and toxicity. Pharmacol. Res. 109 (2016), 119–131.
68. Klinger, R.Y., Habib, A.S., Acetaminophen and ondansetron: the central serotonergic connection. J. Clin. Anesth. 40 (2017), 101–102.
69. Diaz-Gonzalez, F., Sanchez-Madrid, F., NSAIDs: learning new tricks from old drugs. Eur. J. Immunol. 45 (2015), 679–686.
70. Hampton, T., Cox-2 inhibitors and heart risks. JAMA, 307, 2012 2247–2247.
71. Krumholz, H.M., et al. What have we learnt from Vioxx?. BMJ 334 (2007), 120–123.
72. Romundstad, M.D.L., Stubhaug, M.D.P.D.A., Glucocorticoids for acute and persistent postoperative neuropathic pain. What is the evidence?. Anesthesiology 107 (2007), 371–373.
73. Rhen, T., Cidlowski, J.A., Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N. Engl. J. Med. 353 (2005), 1711–1723.
74. Monica, B., Santi, S., Mapracorat, a novel non-ateroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. Inflamm Allergy – Drug Targets 13 (2014), 289–298.
75. Stock, T., et al. Improved disease activity with fosdagrocorat (PF-04271327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study. Int. J. Rheum. Dis. 20 (2017), 960–970.
76. Zeilhofer, H.U., Schmelz, M., Local anesthetics take a central action in analgesia. Pain 156 (2015), 1579–1580.
77. Zakrzewska, J.M., Linskey, M.E., Trigeminal neuralgia. BMJ, 348, 2014, g474.
78. Offord, J., Isom, L.L., Drugging the undruggable: gabapentin, pregabalin and the calcium channel alpha2delta subunit. Crit. Rev. Biochem. Mol. Biol. 51 (2015), 246–256.
79. Gilron, I., et al. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin. Proc. 90 (2015), 532–545.